Royalty Pharma (RPRX) Competitors $36.19 +0.31 (+0.86%) Closing price 04:00 PM EasternExtended Trading$36.20 +0.01 (+0.03%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RPRX vs. ZTS, CORT, JAZZ, PRGO, SUPN, PCRX, OMER, ASMB, NKTR, and CPIXShould you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include Zoetis (ZTS), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Nektar Therapeutics (NKTR), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceuticals" industry. Royalty Pharma vs. Its Competitors Zoetis Corcept Therapeutics Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Omeros Assembly Biosciences Nektar Therapeutics Cumberland Pharmaceuticals Royalty Pharma (NASDAQ:RPRX) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Do insiders and institutionals hold more shares of RPRX or ZTS? 54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor RPRX or ZTS? In the previous week, Zoetis had 12 more articles in the media than Royalty Pharma. MarketBeat recorded 31 mentions for Zoetis and 19 mentions for Royalty Pharma. Zoetis' average media sentiment score of 1.47 beat Royalty Pharma's score of 1.15 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 11 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 26 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, RPRX or ZTS? Royalty Pharma has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Is RPRX or ZTS a better dividend stock? Royalty Pharma pays an annual dividend of $0.88 per share and has a dividend yield of 2.4%. Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.3%. Royalty Pharma pays out 47.6% of its earnings in the form of a dividend. Zoetis pays out 35.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years and Zoetis has increased its dividend for 14 consecutive years. Do analysts rate RPRX or ZTS? Royalty Pharma presently has a consensus target price of $47.33, indicating a potential upside of 30.79%. Zoetis has a consensus target price of $212.13, indicating a potential upside of 33.34%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Royalty Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Royalty Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Zoetis 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has better valuation and earnings, RPRX or ZTS? Zoetis has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoyalty Pharma$2.26B8.99$858.98M$1.8519.56Zoetis$9.26B7.65$2.49B$5.5728.56 Is RPRX or ZTS more profitable? Royalty Pharma has a net margin of 48.23% compared to Zoetis' net margin of 27.12%. Zoetis' return on equity of 55.48% beat Royalty Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Royalty Pharma48.23% 24.71% 13.87% Zoetis 27.12%55.48%19.14% SummaryZoetis beats Royalty Pharma on 15 of the 20 factors compared between the two stocks. Get Royalty Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPRX vs. The Competition Export to ExcelMetricRoyalty PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.17B$2.88B$5.54B$8.87BDividend Yield2.45%2.64%5.39%4.10%P/E Ratio19.5621.3126.1719.90Price / Sales8.99278.47414.67113.66Price / Cash8.5541.4736.1356.90Price / Book2.067.518.055.38Net Income$858.98M-$55.05M$3.15B$248.50M7 Day Performance0.78%2.45%1.85%2.97%1 Month Performance8.81%7.33%4.81%6.02%1 Year Performance39.84%5.38%34.86%20.39% Royalty Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPRXRoyalty Pharma4.9145 of 5 stars$36.19+0.9%$47.33+30.8%+37.0%$20.17B$2.26B19.5680Positive NewsAnalyst DowngradeZTSZoetis4.8304 of 5 stars$157.51+0.2%$212.13+34.7%-7.8%$70.12B$9.29B28.2813,800Positive NewsCORTCorcept Therapeutics4.7142 of 5 stars$74.28+4.1%$138.25+86.1%+112.2%$7.88B$675.04M64.03300Positive NewsJAZZJazz Pharmaceuticals4.9285 of 5 stars$106.76-0.7%$184.00+72.3%+2.8%$6.46B$4.07B14.232,800Positive NewsPRGOPerrigo4.9506 of 5 stars$26.43-0.3%$33.00+24.9%+4.3%$3.63B$4.34B-20.188,379News CoverageSUPNSupernus Pharmaceuticals2.3105 of 5 stars$31.99-0.9%$36.00+12.5%+19.8%$1.79B$661.82M28.82580PCRXPacira BioSciences3.5455 of 5 stars$24.74+2.1%$26.44+6.9%-18.3%$1.15B$700.97M-10.85720Positive NewsOMEROmeros3.7002 of 5 stars$3.19-0.6%$18.00+464.3%-24.8%$186.90MN/A-1.20210Positive NewsAnalyst ForecastASMBAssembly Biosciences3.544 of 5 stars$17.10-1.7%$33.00+93.0%+33.9%$130.64M$28.52M-2.74100News CoverageHigh Trading VolumeNKTRNektar Therapeutics4.6143 of 5 stars$9.54+12.1%$67.50+607.5%+34.4%$118.39M$98.43M-0.99220Analyst RevisionGap DownHigh Trading VolumeCPIXCumberland Pharmaceuticals0.5338 of 5 stars$3.93-9.7%N/A+133.4%$58.79M$37.87M-15.7280Gap Down Related Companies and Tools Related Companies Zoetis Competitors Corcept Therapeutics Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Omeros Competitors Assembly Biosciences Competitors Nektar Therapeutics Competitors Cumberland Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPRX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.